TUSTIN, Calif., Dec. 8, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), developer and marketer of the Onko-Sure® In Vitro Diagnostic (IVD) cancer test, announced today that it has submitted one abstract for the American Society of Colon and Rectal Surgeons' (ASCRS) Annual Meeting to be held in June 2012. ASCRS is the premier society for colon and rectal surgeons and other surgeons dedicated to advancing and promoting the science and practice of the treatment of patients with disease and disorders affecting the colon, rectum and anus.
The title of the abstract submitted is "Combined DR-70 and CEA testing is advantageous over CEA alone in the detection of colorectal cancer and specially the right-sided type." More than 1,000 of the Society's members are certified by the American Board of Colon and Rectal Surgery. The meeting will be held from June 2nd to 6th, 2012 in San Antonio, TX. Over 1,200 surgeons are expected to attend.
If accepted, Robert Beart Jr., M.D., who was appointed to the Company's Board of Directors in June 2010, will make the Company presentation. Dr. Beart currently is the medical director of the Glendale Hospital CRC Institute. Previously he was with the University of Southern California since 1992, establishing the Division of Colorectal Surgery in the USC Department of Surgery as well as launching the USC Center for Colorectal Diseases at USC University Hospital and USC/Norris Cancer Center and Hospital.
Dr. Beart is a recognized specialist and expert in colorectal diseases and cancer, pioneer of the ileal pouch-anal anastomosis, and thought leader in the medical, scientific and research communities. Dr. Beart's primary experience and research includes the identification and management of recurrent colorectal cancer. He has broad and deep clinical involvement in colorectal diseases, covering key areas that include colorect